Navigation Links
Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
Date:1/25/2010

PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 1 clinical study to evaluate ezatiostat hydrochloride (TELINTRA, TLK199) tablets in combination with lenalidomide (Revlimid) in patients with Myelodysplastic Syndrome (MDS).

This Phase 1 trial is an open label, multicenter, dose escalation study of TELINTRA in combination with lenalidomide in patients with non-deletion (5q-) low to intermediate-1 risk MDS.  TELINTRA will be administered in escalating doses in combination with standard dose and schedule lenalidomide.

The study is designed to enroll up to 30 patients and the primary objectives are to assess the safety, tolerability and the maximum tolerated dose of TELINTRA in combination with lenalidomide.  The rationale for the study included non-overlapping toxicities and different mechanisms of action of each component of the combination.

Telik previously reported positive Phase 1 results from a multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) in a leading peer reviewed journal, Blood, 25 June 2009; Vol. 113, No.26, pp. 6533-6540.  Positive results from a separate Phase 1-2A study in MDS patients involving an intravenous formulation of TELINTRA were published in the Journal of Hematology and Oncology, 13 May 2009; Vol. 2, No.10, pp. 20-32.

A Phase 2 Study is ongoing evaluating two different treatment regimens of Telintra in MDS patients, with results expected early this year. In addition, TELINTRA is also being evaluated in a Phase 2 randomized study for the treatment of patient
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
9. Telik Announces Third Quarter 2009 Financial Results
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Conn. , Sept. 1, 2015  Results from ... AD™ study demonstrate that 5g of idarucizumab enabled ... situations involving patients treated with dabigatran (Pradaxa ® ... of the anticoagulant effect of dabigatran enabled patients ... a median time of 1.7 hours between administration ...
(Date:9/1/2015)... , Belgium , Sept. 1, 2015 /PRNewswire/ ... sciences company focused on developing blood-based diagnostic tests for a ... that its Chief Executive Officer, Cameron Reynolds , is ... Healthcare Conference, which is being held September 9-10, 2015 in ... meetings all day on September 10. Wells ...
(Date:9/1/2015)... 2015   Ivenix Inc. , a medical ... closed on a $42M round of equity financing ... Partners, CICA, Inc., Easterly Capital, Fidelity Biosciences, and ... This financing will support the company,s efforts to ... LLC acted as the exclusive placement agent for ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... shows that,polyunsaturated fatty acids (PUFAs), mainly the omega-3s ... function and total parenteral,nutrition (TPN). The June 2008 ... new findings in these areas., One study ... an omega-3 PUFA, and arachidonic acid, an omega-6 ...
... a,division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today,that the ... pediatric,exclusivity for TOPAMAX(R) (topiramate), based on studies submitted ... to investigate the use of TOPAMAX,in pediatric patients ... seizures., In addition to granting pediatric exclusivity, ...
Cached Medicine Technology:Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... the American Society for Dermatologic Surgery, according to a new survey that also ... Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments ...
(Date:9/1/2015)... ... September 01, 2015 , ... Splashtop Inc. , the ... Support , a solution optimized for MSPs and IT professionals looking for a ... and inadequate customer services of existing remote support solution, many MSPs and ITs ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Extension Vending Machine,” is still strongly maintaining her firm’s success in the hair ... tools. In her upcoming city-to-city tour, Ellis will be providing “Look and learn” ...
(Date:9/1/2015)... ... September 01, 2015 , ... OncLive® today ... U.S. News & World Report, to provide breaking news and information about the ... groups within OncLive, which provides oncologists resources and information?they need to deliver the ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The Jerry Segal ... The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over the ... more than $13.5 million for programs and services designed to support patients and their ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3
... Investing in ... ... -- Investing in women and girls during the global financial crisis will help set the ... Director of UNFPA , the United Nations Population Fund. "There is no smarter investment ...
... SUNRISE, Fla., July 9 Bioheart, Inc. (OTC Bulletin ... 1, 2008, and through July 7, 2009, Bioheart, Inc. (the ... the placement of restricted common stock and warrants under its ... number of shares of Common Stock to be issued in ...
... your head where your heart is? It may be now. ... has been suggested in recent clinical studies. As many as ... by periodontal disease and an estimated 80.7 million adults (1 out ... according to the American Heart Association. From the 80.7 million ...
... fewer daily calories boost lifespan , THURSDAY, July 9 (HealthDay ... diet slowed the aging process in monkeys could be the ... for humans. , "The big question in aging research is, ... aging?," said Richard Weindruch, senior author of a paper appearing ...
... the first time on Hospital C o ... hospital readmission rates for Medicare patients with heart attack, ... information for health care consumers, clinicians and hospitals expands ... Quality Alliance (HQA) - a broad working group of ...
... and the Scripps Research Institute have developed an innovative technique ... potential to take the place of the antibodies used in ... the Elizabeth W. Gilloon Professor and professor of chemistry, along ... Chemistry at the Scripps Research Institute and winner of the ...
Cached Medicine News:Health News:World Population Day 2009 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 3Health News:Oral/body inflammatory connection explained 2Health News:Oral/body inflammatory connection explained 3Health News:Lighter Meals May Bring Longer Life 2Health News:Lighter Meals May Bring Longer Life 3Health News:Vital New Quality Data on Hospital Readmission Rates Available on Hospital Compare Website 2Health News:Vital New Quality Data on Hospital Readmission Rates Available on Hospital Compare Website 3Health News:Vital New Quality Data on Hospital Readmission Rates Available on Hospital Compare Website 4Health News:Vital New Quality Data on Hospital Readmission Rates Available on Hospital Compare Website 5Health News:Vital New Quality Data on Hospital Readmission Rates Available on Hospital Compare Website 6Health News:Caltech chemists say antibody surrogates are just a 'click' away 2Health News:Caltech chemists say antibody surrogates are just a 'click' away 3
... This test device is ... detection of IgG and IgM ... human serum. The test is ... for diagnosis of Dengue viral ...
... intended for the immunochromatographic, qualitative determination ... Strip Gonorrhea is based on the ... determination of gonorrhea antigen in the ... system as an aid in the ...
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: